By default, metachronous bladder recurrences after UTUC surgery have been managed similarly to primary non-muscle invasive bladder cancer.

He was previously fined for leaving a towel inside a patient. This is the fourth time in the last eight years his insurance ...

For individuals facing fear, uncertainty and repeated procedures associated with recurrent low-grade intermediate-risk bladder tumors, timely access to treatment can be critical. ZUSDURI, the first ...

Nearly 20,000 women are diagnosed with bladder cancer each year, according to the American Cancer Society, with most being over age 55. And the unfortunate reality is that women are often diagnosed at ...

A Vancouver woman and her husband filed a lawsuit against Legacy Salmon Creek Medical Center and her physician over surgery complications. DeAndras and Ryan Macheras filed the complaint Dec. 11 in ...

“Identifying individuals at high risk for UTIs allows for more targeted treatment and care strategies, thereby enhancing patient safety.” — Yunlan Jiang, Chengdu University of Traditional Chinese ...

MOUNT PLEASANT, S.C. (WCSC) — A new, low-maintenance implant device is now available to residents facing incontinence issues, adding freedom back to the lives of patients. A Lowcountry doctor has ...

KNOXVILLE, Tenn — According to the Knox County Sheriff's Office, Deputy Dalton Swanger's tracheal resection surgery has been scheduled for later this month. Including the surgery Swanger underwent ...

The U.S. Food and Drug Administration has approved Pfizer's Padcev (enfortumab vedotin-ejfv), a Nectin-4 directed antibody-drug conjugate, as a perioperative neoadjuvant treatment and postcystectomy ...

An experimental treatment method has shown promise in fighting a hard-to-treat form of bladder cancer known as BCG-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC). BCG (Bacillus ...

Signatera detects molecular residual disease in bladder cancer by identifying tumor DNA fragments in the bloodstream, even when not visible on scans. The IMvigor010 trial showed that Signatera-guided ...